These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 30038044)
1. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Cathcart AL; Chan HL; Bhardwaj N; Liu Y; Marcellin P; Pan CQ; Shalimar ; Buti M; Cox S; Parhy B; Zhou E; Martin R; Chang S; Lin L; Flaherty JF; Kitrinos KM; Gaggar A; Izumi N; Lim YS Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30038044 [TBL] [Abstract][Full Text] [Related]
2. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ; J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595 [TBL] [Abstract][Full Text] [Related]
3. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. Liu Y; Corsa AC; Buti M; Cathcart AL; Flaherty JF; Miller MD; Kitrinos KM; Marcellin P; Gane EJ J Viral Hepat; 2017 Jan; 24(1):68-74. PubMed ID: 27658343 [TBL] [Abstract][Full Text] [Related]
4. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Kitrinos KM; Corsa A; Liu Y; Flaherty J; Snow-Lampart A; Marcellin P; Borroto-Esoda K; Miller MD Hepatology; 2014 Feb; 59(2):434-42. PubMed ID: 23939953 [TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224 [TBL] [Abstract][Full Text] [Related]
6. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235 [TBL] [Abstract][Full Text] [Related]
7. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939 [TBL] [Abstract][Full Text] [Related]
8. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Ogawa E; Furusyo N; Nguyen MH Drug Des Devel Ther; 2017; 11():3197-3204. PubMed ID: 29158666 [TBL] [Abstract][Full Text] [Related]
9. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety. Chan HLY; Buti M; Lim YS; Agarwal K; Marcellin P; Brunetto M; Chuang WL; Janssen HLA; Fung S; Izumi N; Abdurakhmanov D; Jabłkowski M; Celen MK; Ma X; Caruntu F; Flaherty JF; Abramov F; Wang H; Camus G; Osinusi A; Pan CQ; Shalimar ; Seto WK; Gane E; Am J Gastroenterol; 2024 Mar; 119(3):486-496. PubMed ID: 37561058 [TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P; Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092 [TBL] [Abstract][Full Text] [Related]
12. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795 [TBL] [Abstract][Full Text] [Related]
13. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Snow-Lampart A; Chappell B; Curtis M; Zhu Y; Myrick F; Schawalder J; Kitrinos K; Svarovskaia ES; Miller MD; Sorbel J; Heathcote J; Marcellin P; Borroto-Esoda K Hepatology; 2011 Mar; 53(3):763-73. PubMed ID: 21374657 [TBL] [Abstract][Full Text] [Related]
14. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Abdul Basit S; Dawood A; Ryan J; Gish R Expert Rev Clin Pharmacol; 2017 Jul; 10(7):707-716. PubMed ID: 28460547 [TBL] [Abstract][Full Text] [Related]
16. Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance. Liu Y; Chang S; Martin R; Flaherty J; Mo H; Feierbach B J Viral Hepat; 2021 Jan; 28(1):30-39. PubMed ID: 32894807 [TBL] [Abstract][Full Text] [Related]
17. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597 [TBL] [Abstract][Full Text] [Related]
18. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. Pan CQ; Chang TT; Bae SH; Brunetto M; Seto WK; Coffin CS; Tan SK; Mo S; Flaherty JF; Gaggar A; Nguyen MH; Çelen MK; Thompson A; Gane EJ PLoS One; 2021; 16(5):e0251552. PubMed ID: 33984038 [TBL] [Abstract][Full Text] [Related]
19. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Viganò M; Loglio A; Grossi G; Lampertico P Expert Rev Anti Infect Ther; 2018 Feb; 16(2):153-161. PubMed ID: 29338458 [TBL] [Abstract][Full Text] [Related]
20. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]